Centralized Reminder/Recall to Increase Influenza Vaccination Rates: A Two-State Pragmatic Randomized Trial.
Adolescent
Child
Child, Preschool
Colorado
Cost-Benefit Analysis
Female
Humans
Infant
Influenza Vaccines
/ economics
Influenza, Human
/ prevention & control
Male
New York
Primary Health Care
Reminder Systems
Rural Population
/ statistics & numerical data
Surveys and Questionnaires
Urban Population
/ statistics & numerical data
Vaccination
/ economics
centralized reminder/recall
influenza vaccine
pediatrics
population-based reminder/recall
Journal
Academic pediatrics
ISSN: 1876-2867
Titre abrégé: Acad Pediatr
Pays: United States
ID NLM: 101499145
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
16
07
2019
revised:
28
10
2019
accepted:
30
10
2019
pubmed:
8
11
2019
medline:
18
3
2021
entrez:
8
11
2019
Statut:
ppublish
Résumé
Centralized reminder/recall (C-R/R) by health departments using immunization information systems is more effective and cost effective than practice-based approaches for increasing childhood vaccines but has not been studied for influenza vaccination. We assessed effectiveness and cost of C-R/R for increasing childhood influenza vaccination compared with usual care. Within Colorado (CO) and New York (NY), random samples of primary care practices (pediatric, family medicine, and health center) were selected proportionate to where children are served-65 practices (N = 54,353 children) in CO; 101 practices (N = 65,777) in NY. We conducted 4-arm RCTs per state (1, 2, or 3 autodial reminders vs usual care), with randomization at the patient level within practices from 10/2016 to 1/2017. In CO, the maximum absolute difference in receipt of ≥1 influenza vaccine was 1.7% between the 2 R/R group and control (adjusted risk ratio [ARR] of 1.06 [1.01, 1.10]); other R/R arms did not differ significantly. In NY, ARRs for the study arms versus control varied from 1.05 (1.01, 1.10) for 3 R/R to 1.06 (1.01, 1.11) for 1-2 R/R groups and maximum absolute increase in vaccination was 0.6%. In time-to-event analyses, study arm was a significant predictor of vaccination in CO (P = .001) but not in NY. Costs/child randomized to one message were $.17 in CO and $.23 in NY. C-R/R for influenza vaccine using autodial had low-level effects on increasing influenza rates in 2 states. Given the feasibility and low cost of C-R/R in previous trials, its utility for influenza should be re-examined using different modalities.
Identifiants
pubmed: 31698085
pii: S1876-2859(19)30449-8
doi: 10.1016/j.acap.2019.10.015
pmc: PMC7477488
mid: NIHMS1541989
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02761551', 'NCT02924467']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
374-383Subventions
Organisme : NIAID NIH HHS
ID : R01 AI114903
Pays : United States
Informations de copyright
Copyright © 2019 Academic Pediatric Association. Published by Elsevier Inc. All rights reserved.
Références
JAMA Pediatr. 2015 Apr;169(4):365-73
pubmed: 25706340
N Engl J Med. 2006 Jul 6;355(1):31-40
pubmed: 16822994
BMC Med Inform Decis Mak. 2012 Dec 17;12:145
pubmed: 23245381
Pediatrics. 2005 Jan;115(1):146-54
pubmed: 15629993
MMWR Recomm Rep. 2017 Aug 25;66(2):1-20
pubmed: 28841201
J Adolesc Health. 2018 Feb;62(2):157-163
pubmed: 29248390
Pediatrics. 2003 Nov;112(5):1076-82
pubmed: 14595049
Euro Surveill. 2013 Jan 31;18(5):
pubmed: 23399425
Vaccine. 2018 Aug 6;36(32 Pt B):4904-4909
pubmed: 30037480
JAMA. 2012 Apr 25;307(16):1702-8
pubmed: 22535855
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
MMWR Morb Mortal Wkly Rep. 2010 Apr 30;59(16):477-84
pubmed: 20431523
JAMA. 2000 Oct 11;284(14):1820-7
pubmed: 11025835
Acad Pediatr. 2016 Jan-Feb;16(1):50-6
pubmed: 26525988
Cochrane Database Syst Rev. 2018 Jan 18;1:CD003941
pubmed: 29342498
MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):10-5
pubmed: 25590680
Acad Pediatr. 2018 Mar;18(2S):S72-S78
pubmed: 29502641
PLoS One. 2017 Jan 26;12(1):e0170550
pubmed: 28125629
Pediatrics. 2016 Mar;137(3):e20153280
pubmed: 26908692
MMWR Recomm Rep. 2008 Aug 8;57(RR-7):1-60
pubmed: 18685555
Clin Infect Dis. 2020 Jun 10;70(12):2496-2502
pubmed: 31344229
Acad Pediatr. 2018 Nov - Dec;18(8):873-881
pubmed: 30031132
Acad Pediatr. 2011 Jan-Feb;11(1):44-9
pubmed: 21272823
Vaccine. 2015 Apr 8;33(15):1802-7
pubmed: 25744225
MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43
pubmed: 24048214
J Infect Dis. 2002 Jan 15;185(2):147-52
pubmed: 11807687
BMC Public Health. 2006 Feb 15;6:33
pubmed: 16480494
Am J Public Health. 2013 Jun;103(6):1116-23
pubmed: 23237154
Lancet Infect Dis. 2013 Jan;13(1):7-9
pubmed: 23257219
Am J Prev Med. 2000 Jan;18(1 Suppl):97-140
pubmed: 10806982
Acad Pediatr. 2014 May-Jun;14(3):234-40
pubmed: 24767776
Am J Prev Med. 2012 Jan;42(1):71-5
pubmed: 22176850